Randomized Controlled Trial to Study the Outcome of Intravenous Phosphate Supplementation in Live Donors Undergoing Hepatectomy for Living Donor Liver Transplantation (LDLT)
Launched by INSTITUTE OF LIVER AND BILIARY SCIENCES, INDIA · Jul 17, 2019
Trial Information
Current as of April 28, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All donors evaluated as per institutional protocol for donor hepatectomy and found fit
- • Those who consent.
- Exclusion Criteria:
- • Patients refusing to consent for inclusion in the study.
- • Minor hepatectomy
- • Those who develop profound hypophosphatemia in the control group
About Institute Of Liver And Biliary Sciences, India
The Institute of Liver and Biliary Sciences (ILBS) in India is a premier research and healthcare institution dedicated to the advancement of knowledge and treatment in liver, biliary, and related diseases. As a clinical trial sponsor, ILBS is committed to conducting innovative and ethically-driven research to improve patient outcomes and enhance therapeutic options in hepatology. The institute fosters collaboration among multidisciplinary teams of clinicians, researchers, and healthcare professionals, ensuring rigorous scientific methodologies and adherence to regulatory standards. Through its focus on translational research, ILBS aims to bridge the gap between laboratory discoveries and clinical applications, ultimately contributing to the global understanding and management of liver diseases.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Delhi, , India
Patients applied
Trial Officials
Viniyendra Pamecha, Professor
Study Chair
Professor and Head, Department of HPB surgery and Liver transplantation, ILBS, New Delhi.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials